About the Study

High Risk Medulloblastoma: A clinical study of elfornithine/DFMO as maintenance therapy after standard treatment

This study is for: • Patients who are between the ages of 0 and 21 years old • Who have been diagnosed with molecular high risk medulloblastoma, very high risk medulloblastoma, or medulloblastoma that has relapsed (has come back) or is refractory (has not responded to earlier treatment) The goal of this research study is to find the effects, good and/or bad, the investigational drug eflornithine HCl (DFMO) has on high risk and very high risk medulloblastoma. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This study will look at the ability of this study drug to either keep the tumors in remission or, if for active tumors, for the tumors to respond to the treatment. It will also look at the safety and tolerability of DFMO.

Interested in learning more?

Full Study Name: BCC016 Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma